AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25522919
Drug: Ultrasound-guided corticosteroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided corticosteroid injection (1 ml containing 40 mg methylprednisolone acetate and 10 mg lidocaine hydrochloride)
Trial: 24022261
Drug: Once-weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly iron supplements (200 mg ferrous sulphate containing 63 mg of elemental iron) for 24 weeks
Trial: 24022261
Drug: Twice-weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly iron supplements (200 mg ferrous sulphate containing 63 mg of elemental iron) for 12 weeks
Trial: 24022261
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron supplements
Trial: 9068511
Drug: Angiography after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiography after treatment with thrombolytics
Trial: 7513437
Drug: Finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 1 mg/die
Trial: 7513437
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg/die
Trial: 7513437
Drug: Placebo (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (first year), then Finasteride 5 mg/die (second year)
Trial: 25808116
Drug: 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/day of milled flaxseed
Trial: 25808116
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of milled flaxseed
Trial: 25808116
Drug: All flaxseed
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All flaxseed doses
Trial: 25808116
Drug: 40 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/day of milled flaxseed
Trial: 16042224
Drug: IFNbeta‐1a (Avonex)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta‐1a (Avonex) once weekly
Trial: 16042224
Drug: IFNbeta three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNbeta three times weekly (Rebif and Betaferon)
Trial: 16042224
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with immunomodulatory drugs (IDs)
Trial: 12183255
Drug: 1263W94 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1263W94 (100, 200, or 400 mg three times a day, or 600, 900, or 1,200 mg twice a day)
Trial: 10624380
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg, three times daily for 24 weeks
Trial: 10624380
Drug: Placebo capsules,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, three times daily for 24 weeks
Trial: 2258339
Drug: Pefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (400 mg, iv, 8-hourly) for 5-30 days
Trial: 2258339
Drug: Imipenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (1 g, iv, 8-hourly) for 5-30 days
Trial: 31959342
Drug: Standard-dose radium-223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose radium-223 (55 kBq/kg every 4 weeks for six cycles)
Trial: 31959342
Drug: High-dose radium-223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radium-223 (88 kBq/kg every 4 weeks for six cycles)
Trial: 31959342
Drug: High-dose vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vs Standard-dose
Trial: 31959342
Drug: Standard-dose radium-223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose radium-223
Trial: 31959342
Drug: High-dose radium-223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radium-223
Trial: 21349878
Drug: Open treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open treatment with a scalpel
Trial: 21349878
Drug: Percutaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous treatment with a needle
Trial: 17715118
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 900 mg injection 1 hour before and immediately after contrast medium injection, plus hydration
Trial: 12612144
Drug: Campbell's Condensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campbell's Condensed Tomato Soup (CS) - 35 +/- 1 mg lycopene/d
Trial: 12612144
Drug: Campbell's Ready
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campbell's Ready To Serve Tomato Soup (RTS) - 23 +/- 1 mg lycopene/d
Trial: 12612144
Drug: V8 Vegetable
RxNorm normalized name: VEGETABLE CARBON
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V8 Vegetable Juice (V8) - 25 +/- 1 mg lycopene/d
Trial: 12612144
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups after treatment
Trial: 10373348
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant human insulin-like growth factor-I (rhIGF-I; 1.5 microg/kg/h)
Trial: 10373348
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant human insulin-like growth factor-I (rhIGF-I; 9.0 microg/kg/h)
Trial: 6770399
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (up to 10 mg)
Trial: 22277556
Drug: Riboflavin (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin (1.6 mg/d for 16 wk)
Trial: 19281446
Drug: Normal Level
RxNorm normalized name: GE100 Normal Level Control Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Level of Replacement Therapy
Trial: 19281446
Drug: Augmented Level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented Level of Replacement Therapy
Trial: 17685917
Drug: Prophylaxis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis with routine infusions of factor VIII (FVIII) concentrate
Trial: 17685917
Drug: On-demand FVIII
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand FVIII treatment
Trial: 17685917
Drug: Escalating dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose frequency of prophylaxis
Trial: 9641318
Drug: External tones
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External tones presented as 250 ms pulses, twice a second.
Trial: 9641318
Drug: Consumption of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of aspirin by one subject.
Trial: 8086551
Drug: iv clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv clindamycin (900 mg every 8 hours for 10 days, then oral clindamycin (450 mg every 6 hours for 11 days) + oral primaquine (30 mg once daily)
Trial: 8086551
Drug: oral clindamycin
RxNorm normalized name: clindamycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral clindamycin (600 mg every 8 hours) + oral primaquine (30 mg once daily)
Trial: 31857511
Drug: SVV-guided fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SVV-guided fluid therapy (group S)
Trial: 27598342
Drug: Local muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local muscle vibration treatment (300 Hz, 30 minutes, 3 times per week for 12 sessions)
Trial: 24960439
Drug: Unified Protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified Protocol for the Treatment of Emotional Disorders in Adolescence (UP-A)
Trial: 22295884
Drug: Drotaverine hydrochloride
RxNorm normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotaverine hydrochloride (80 mg)
Trial: 19856067
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin 500 mg once daily
Trial: 14728019
Drug: Transfer for
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer for primary angioplasty without fibrinolytic treatment
Trial: 9236500
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 50 micrograms
Trial: 9236500
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 100 micrograms
Trial: 9236500
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 200 micrograms
Trial: 9236500
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 800 micrograms
Trial: 8422174
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 600 mg/body of UFT continuously administered every day for 1 year.
Trial: 8422174
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 400 mg/body of UFT every day and the same amount of MMC as Group C.
Trial: 8422174
Drug: UFT dosage
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT dosage per body weight (kg) of 8-12 mg/kg.
Trial: 2446056
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg b.i.d. after 2 weeks of 20 mg b.i.d.)
Trial: 2446056
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg N retard b.i.d.)
Trial: 27488574
Drug: AMP XR-ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP XR-ODT (18.8 mg)
Trial: 27488574
Drug: AMP XR-ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP XR-ODT (18.8 mg) with food
Trial: 27488574
Drug: MAS ER
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAS ER (30 mg)
Trial: 25376790
Drug: Apatinib 500
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500 mg daily on days 1 through 28 of each 4-week cycle
Trial: 23760573
Drug: Tagatose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagatose (5 g)
Trial: 23760573
Drug: Tagatose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tagatose (10 g)
Trial: 18213452
Drug: Simvastatin delayed
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin delayed release tablet (20 mg)
Trial: 18213452
Drug: Simvastatin immediate
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin immediate release capsule (20 mg)
Trial: 18213452
Drug: Simvastatin immediate
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin immediate release tablet Zocor (20 mg)
Trial: 12612979
Drug: Atorvastatin in
RxNorm normalized name: Product containing atorvastatin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin in addition to ACE inhibitors and ARBs
Trial: 12612979
Drug: No atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No atorvastatin in addition to ACE inhibitors and ARBs
Trial: 8612120
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of astemizole
Trial: 8612120
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of cetirizine
Trial: 8612120
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cetirizine
Trial: 29117764
Drug: LAM + EC (counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM + EC (counseling and in advance provision of one packet of 0.75‐mg LNG‐ECPs)
Trial: 29176387
Drug: CODJ-G (complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODJ-G (complex COD and plyometric protocol)
Trial: 29176387
Drug: COD-G (isolated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COD-G (isolated COD protocol)
Trial: 27569118
Drug: Moderate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate daily caloric restriction (CR)
Trial: 25040146
Drug: 50% reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduction of angiotensin inhibitor dose (n=30)
Trial: 25040146
Drug: Standard basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard basal dose of angiotensin inhibitors (n=16)
Trial: 14748937
Drug: High-protein, high-sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein, high-sodium diet (90 g/d protein, 180 mmol/d Na)
Trial: 14748937
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet (70 g/d protein, 65 mmol/d Na)
Trial: 7939431
Drug: Oral teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral teicoplanin 100 mg twice daily for 7 days (BID group)
Trial: 7939431
Drug: Oral teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral teicoplanin 50 mg 4 times daily for 3 days, followed by 100 mg twice daily for 4 days (QID group)
Trial: 3283457
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with tamoxifen
Trial: 3283457
Drug: Receptor-positive tumors
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receptor-positive tumors
Trial: 3283457
Drug: Receptor-negative tumors
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receptor-negative tumors
Trial: 23107971
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose gemcitabine (1,000 mg/m2) with carboplatin (AUC 5)
Trial: 23107971
Drug: Low-dose prolonged
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prolonged infusion gemcitabine (350 mg/m2) with carboplatin (AUC 5)
Trial: 20122038
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control group (two brief 'check-in' telephone calls during 6 months)
Trial: 10235192
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg, clarithromycin 500 mg, and amoxicillin 1 g, all given b.i.d. for 10 days
Trial: 10235192
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate, amoxicillin, and clarithromycin (10-day therapy)
Trial: 8557125
Drug: Agonist administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agonist administered irrespective of cycle phase
Trial: 7078423
Drug: Bendroflumethiazide 5
RxNorm normalized name: bendroflumethiazide 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 5 mg/day
Trial: 28359339
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg for 2 weeks before surgery
Trial: 28359339
Drug: No change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No change to current statin therapy
Trial: 22015451
Drug: Single-dose rasburicase
RxNorm normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-dose rasburicase (0.15 mg/kg)
Trial: 22015451
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of rasburicase for 5 days
Trial: 19509098
Drug: Clomiphene, metformin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomiphene, metformin, or combination of both for up to six cycles
Trial: 17244248
Drug: Interferon-alpha-2a monotherapy
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2a monotherapy (9 MUI/day for 4 weeks and then 3 MUI/3 t.i.w. for 44 weeks)
Trial: 17244248
Drug: Interferon-alpha-2a +
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2a + Amantadine (100 mg twice daily for 48 weeks)
Trial: 17244248
Drug: Interferon-alpha-2a +
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha-2a + Ribavirin (1000-1200 mg)
Trial: 9830234
Drug: Controlled-release 5-ISMN
RxNorm normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release 5-ISMN 60 mg once daily
Trial: 9830234
Drug: Conventional 5-ISMN
RxNorm normalized name: ISMN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional 5-ISMN 20 mg twice daily
Trial: 8132132
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 to 10mg oral, given at bedtime)
Trial: 3777565
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion method (Group B)
Trial: 18562775
Drug: Low-GI/Low-GL meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-GI/Low-GL meal (L-L) - Carbohydrate content 65%, GI 40, GL 42
Trial: 18562775
Drug: High-GI/Low-GL meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-GI/Low-GL meal (H-L) - Carbohydrate content 36%, GI 78, GL 44
Trial: 9075595
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor-based treatment
Trial: 11901278
Drug: Diuretic-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic-based treatment
Trial: 3530834
Drug: 1% ciclopirox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ciclopirox olamine cream
Trial: 27329657
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg intravenous at 0, 2, and 6 weeks)
Trial: 27329657
Drug: Ciclosporin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (2 mg/kg/day intravenous for 7 days followed by 5.5 mg/kg/day oral until 12 weeks)
Trial: 24576533
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (various)
Trial: 22105061
Drug: Buprenorphine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine therapy in an opioid treatment program (OTP) with individual counseling
Trial: 22105061
Drug: Buprenorphine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine therapy in a group counseling program utilizing the Matrix Model (MMM)
Trial: 22105061
Drug: Buprenorphine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine therapy in a private clinic setting mirroring standard medical management
Trial: 15768813
Drug: 100 mg/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/l topical amphotericin B
Trial: 15768813
Drug: 50 mg/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/l topical amphotericin B
Trial: 9738066
Drug: BHI-VAN broth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BHI-VAN broth (brain heart infusion broth, horse serum, and yeast extract supplemented with vancomycin, amphotericin B, and nalidixic acid)
Trial: 3046382
Drug: Imipramine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (low oral doses)
Trial: 25624196
Drug: Long GnRH
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long GnRH agonist cycles
Trial: 25624196
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist cycles
Trial: 18756943
Drug: Activated carbon
RxNorm normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated carbon nanoparticles injection (either by endoscopic injection or intraoperative subserosal injection)
Trial: 18756943
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no activated carbon nanoparticles injection)
Trial: 18756943
Drug: Activated carbon
RxNorm normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated carbon nanoparticles injection
Trial: 10037380
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for 1 month
Trial: 21808844
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg midazolam
Trial: 7740908
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of meperidine 6.0 mg/mL, atropine 0.08 mg/mL, and diazepam 0.6 mg/mL (0.2 mL/kg)